A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European organization for research and treatment of cancer (EORTC) study 22844

被引:458
作者
Karim, ABMF
Maat, B
Hatlevoll, R
Menten, J
Rutten, EHJM
Thomas, DGT
Mascarenhas, F
Horiot, JC
Parvinen, LM
vanReijn, M
Hamers, HP
Gaspar, L
Noordman, E
Pierart, M
vanGlabbeke, M
vanAlphen, AM
Jager, JJ
Fabrini, MG
机构
[1] FREE UNIV AMSTERDAM HOSP,DEPT RADIAT ONCOL,AMSTERDAM,NETHERLANDS
[2] BV INST,DEPT RADIAT ONCOL,TILBURG,NETHERLANDS
[3] UNIV RADIUM HOSP,DEPT RADIAT ONCOL,OSLO,NORWAY
[4] UNIV HOSP,DEPT RADIAT ONCOL,LOUVAIN,BELGIUM
[5] UNIV NIJMEGEN HOSP,DEPT RADIAT ONCOL,NL-6500 HB NIJMEGEN,NETHERLANDS
[6] QUEENS SQ NEUROL INST,DEPT NEUROSURG,LONDON,ENGLAND
[7] UNIV LISBON,HOSP SANTA MARIA,DEPT RADIAT ONCOL,P-1699 LISBON,PORTUGAL
[8] DIJON UNIV HOSP,DEPT RADIAT ONCOL,DIJON,FRANCE
[9] TURKU CENT HOSP,DEPT RADIAT ONCOL,TURKU,FINLAND
[10] ENSCHEDE HOSP,DEPT RADIAT ONCOL,ENSCHEDE,NETHERLANDS
[11] MAASTRICHT UNIV HOSP,DEPT RADIAT ONCOL,MAASTRICHT,NETHERLANDS
[12] PISA UNIV HOSP,DEPT RADIAT ONCOL,PISA,ITALY
[13] FREE UNIV AMSTERDAM HOSP,DEPT NEUROSURG,AMSTERDAM,NETHERLANDS
[14] RADIOTHERAPY INST,DEPT RADIAT ONCOL,TILBURG,NETHERLANDS
[15] LISBON UNIV HOSP,DEPT RADIAT ONCOL,LISBON,PORTUGAL
[16] EORTC,BRUSSELS,BELGIUM
[17] TURKU UNIV HOSP,DEPT RADIAT ONCOL,FIN-20520 TURKU,FINLAND
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1996年 / 36卷 / 03期
关键词
low-grade glioma; radiotherapeutic dose-response; T of the TNM staging classification; prognostic factors;
D O I
10.1016/S0360-3016(96)00352-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Cerebral low-grade gliomas (LGG) in adults are mostly composed of astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas. There is at present no consensus in the policy of treatment of these tumors. We sought to determine the efficacy of radiotherapy and the presence of a dose-response relationship for these tumors in two multicentric randomized trials conducted by the European Organization for Research and Treatment of Cancer (EORTC). The dose-response study is the subject of this article. Methods and Materials: For the dose-response trial, 379 adult patients with cerebral LGGs were randomized centrally at the EORTC Data Center to receive irradiation postoperatively (or postbiopsy) with either 45 Gy in 5 weeks or 59.4 Gy in 6.6 weeks with quality-controlled radiation therapy. All known parameters with possible influences on prognosis were prospectively recorded. Conventional treatment techniques were recommended. Results: With 343 (91%) eligible and evaluable patients followed up for at least 50 months with a median of 74 months, there is no significant difference in terms of survival (58% for the low-dose arm and 59% for the high-dose arm) or the progression free survival (47% and 50%) between the two arms of the trial However, this prospective trial has revealed some important facets about the prognostic parameters: The T of the TNM classifications as proposed in the protocol appears to be one of the most important prognostic factors (p < 0.0001) on multivariate analysis. Other prognostic factors, most of which are known, have now been quantified and confirmed in this prospective study. Conclusion: The EORTC trial 22844 has not revealed the presence of radiotherapeutic dose-response for patients with LGG for the two dose levels investigated with this conventional setup, but objective prognostic parameters are recognized. The tumor size or T parameter as used in this study appears to be a very important factor. Copyright (C) 1996 Elsevier Science Inc.
引用
收藏
页码:549 / 556
页数:8
相关论文
共 20 条
  • [1] AFRA D, 1991, GLIOMA PRINCIPLES PR, P189
  • [2] BERGER MS, 1994, CANCER, V74, P1784, DOI 10.1002/1097-0142(19940915)74:6<1784::AID-CNCR2820740622>3.0.CO
  • [3] 2-D
  • [4] COX DR, 1972, J R STAT SOC B, V34, P187
  • [5] TREATMENT OF GRADES-1 AND GRADES-2 BRAIN ASTROCYTOMAS - ROLE OF RADIOTHERAPY
    FAZEKAS, JT
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1977, 2 (7-8): : 661 - 666
  • [6] GARCIA DM, 1985, CANCER, V55, P919, DOI 10.1002/1097-0142(19850301)55:5<919::AID-CNCR2820550502>3.0.CO
  • [7] 2-4
  • [8] HARMANEK P, 1987, TNM CLASSIFICATION M, P219
  • [9] *INT COMM RAD UN M, 1978, ICRU REP, V29, P3
  • [10] JANNY P, 1994, CANCER, V73, P1937, DOI 10.1002/1097-0142(19940401)73:7<1937::AID-CNCR2820730727>3.0.CO